Patents by Inventor Michael R. Hale

Michael R. Hale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED AMIDE MACROCYCLIC COMPOUNDS WITH OREXIN-2 RECEPTOR AGONIST ACTIVITY
    Publication number: 20240124485
    Abstract: The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Application
    Filed: October 3, 2023
    Publication date: April 18, 2024
    Inventors: Younggi Choi, Yuan Hu, Hoan Huynh, Brian M. Aquila, Brian Kenneth Raymer, Ingo Andreas Mugge, James R. Woods, Lewis D. Pennington, Jörg Martin Bentzien, Jonathan Ward Lehmann, Michael R. Hale, Roman A. Valiulin
  • SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT
    Publication number: 20230339969
    Abstract: The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Application
    Filed: November 22, 2022
    Publication date: October 26, 2023
    Inventors: Lewis D. Pennington, Younggi Choi, Hoan Huynh, Brian M. Aquila, Ingo Andreas Mugge, Yuan Hu, James R. Woods, Roman A. Valiulin, Brian Kenneth Raymer, Jörg Martin Bentzien, Michael R. Hale, Jonathan Ward Lehmann, Daljit Matharu, Srinivasa Karra
  • Self regulating modular battery
    Patent number: 11784358
    Abstract: A self-regulating battery may generate a basis state for one or more modules using one or more system inputs. The system inputs comprise current, voltage, and battery degradation. The battery generates a family of weighted forecasts for future bus demands using usage and performance based weights. The battery generates one or more plans to support demand from the battery using the weighted forecasts. The battery scores the one or more plans based on efficiency of power extraction from the battery, and combines the scored one or more plans with an updated SoH value based on induced degradation from a usage plan. The battery generates the combined scored for each of the one or more plans, and transmits one of the combined scored to the battery management unit for execution.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: October 10, 2023
    Assignee: THE AEROSPACE CORPORATION
    Inventors: Eric Joseph Nemanick, Ann L. Chervenak, Joseph Z. Fuerst, Andrew Brethorst, Michael R. Hale, Kevin Macdougall, Justin Stocker
  • Complement Modulators and Related Methods
    Publication number: 20230115176
    Abstract: The present disclosure presents compounds and compositions that interact with complement components. Some compounds inhibit complement activity. Included are small molecule compounds and compositions that function as C5 inhibitor compounds. Methods for inhibiting complement activity and methods of treating complement-related indications with the C5 inhibitor compounds and compositions are provided.
    Type: Application
    Filed: March 27, 2020
    Publication date: April 13, 2023
    Inventors: Willmen Wing-Menn Youngsaye, Bolin Geng, Michael R. Hale, Vincent P. Galullo, Jayashree G. Tikhe, Timothy Ryan Siegert, Alonso Ricardo, Derek M. LaPlaca, Douangsone D. Vadysirisack, Guo-Qing Tang, Kathleen Seyb, Michelle Denise Hoarty, Jonathan C. Blain, Joseph R. Stringer, Yongjin Gong, Claudio Sturino, Shawn Gallagher-Duval, Colin Diner, Burcin Akgun, Qing Cao, Douglas A. Treco, Vaishnavi Rajagopal, Ketki Ashok Dhamnaskar, Zhong Ma, Susan Ashwell, Jennifer Davoren, Xiaorong Liu, Camil Sayegh, Wenqing Xu, Alex Lemire, Audrey Belouin, Alexandria Jeanneret, Andrew Hildering, Barbara Bertani, Fabrizio MIcheli, Bemardo Pezzati, Alfonso Pozzan
  • SELF REGULATING MODULAR BATTERY
    Publication number: 20230012390
    Abstract: A self-regulating battery may generate a basis state for one or more modules using one or more system inputs. The system inputs comprise current, voltage, and battery degradation. The battery generates a family of weighted forecasts for future bus demands using usage and performance based weights. The battery generates one or more plans to support demand from the battery using the weighted forecasts. The battery scores the one or more plans based on efficiency of power extraction from the battery, and combines the scored one or more plans with an updated SoH value based on induced degradation from a usage plan. The battery generates the combined scored for each of the one or more plans, and transmits one of the combined scored to the battery management unit for execution.
    Type: Application
    Filed: July 7, 2021
    Publication date: January 12, 2023
    Applicant: The Aerospace Corporation
    Inventors: Eric Joseph NEMANICK, Ann L. CHERVENAK, Joseph Z. FUERST, Andrew BRETHORST, Michael R. HALE, Kevin MACDOUGALL, Justin STOCKER
  • Substituted macrocyclic compounds and related methods of treatment
    Patent number: 11542276
    Abstract: The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: January 3, 2023
    Assignee: Alkermes, Inc.
    Inventors: Lewis D. Pennington, Younggi Choi, Hoan Huynh, Brian M. Aquila, Ingo Andreas Mugge, Yuan Hu, James R. Woods, Roman A. Valiulin, Brian Kenneth Raymer, Jörg Martin Bentzien, Michael R. Hale, Jonathan Ward Lehmann, Daljit Matharu, Srinivasa Karra
  • Substituted Macrocyclic Compounds and Related Methods of Treatment
    Publication number: 20220194958
    Abstract: The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Application
    Filed: December 20, 2021
    Publication date: June 23, 2022
    Inventors: Lewis D. Pennington, Younggi Choi, Hoan Huynh, Brian M. Aquila, Ingo Andreas Mugge, Yuan Hu, James R. Woods, Brian Kenneth Raymer, Jörg Martin Bentzien, Jonathan Ward Lehmann, Michael R. Hale, Srinivasa Karra, Roman A. Valiulin, Daljit Matharu
  • Substituted Macrocyclic Compounds and Related Methods of Treatment
    Publication number: 20210155636
    Abstract: The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
    Type: Application
    Filed: November 25, 2020
    Publication date: May 27, 2021
    Inventors: Lewis D. Pennington, Younggi Choi, Hoan Huynh, Brian M. Aquila, Ingo Mugge, Yuan HU, James R. Woods, Roman A. Valiulin, Brian Kenneth Raymer, Jorg Martin Bentzien, Michael R. Hale, Jonathan Ward Lehmann, Daljit Matharu, Srinivasa Karra
  • Inhibitors of aspartyl protease
    Patent number: 8455497
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: June 4, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael R. Hale, Roger Tung, Stephen Price, Robin David Wilkes, Wayne Carl Schairer, Ashley Nicholas Jarvis, Andrew Spaltenstein, Eric Steven Furfine, Vicente Samano, Istvan Kaldor, John Franklin Miller, Michael Stephen Brieger, Ronald George Sherrill
  • Inhibitors of aspartyl protease
    Patent number: 7919523
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: April 5, 2011
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: Michael R. Hale, Christopher T. Baker, Timothy A. Stammers, Ronald George Sherrill, Andrew Spaltenstein, Eric Steven Furfine, Francois Maltais, Clarence Webster Andrews, III, John Franklin Miller, Vicente Samano
  • INHIBITORS OF ASPARTYL PROTEASE
    Publication number: 20090274650
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Application
    Filed: February 12, 2009
    Publication date: November 5, 2009
    Inventors: Michael R. Hale, Roger Tung, Stephen Price, Robin David Wilkes, Wayne Carl Schairer, Ashley Nicholas Jarvis, Andrew Spaltenstein, Eric Steven Furfine, Vicente Samano, Istvan Kaldor, John Franklin Miller, Michael Stephen Brieger, Ronald George Sherrill
  • Inhibitors of aspartyl protease
    Publication number: 20090042973
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Application
    Filed: July 2, 2008
    Publication date: February 12, 2009
    Inventors: Michael R. Hale, Christopher T. Baker, Timothy A. Stammers, Ronald George Sherrill, Andrew Spaltenstein, Eric Steven Furfine, Francois Maltais, Clarence Webster Andrews, III, John Franklin Miller, Vicente Samano
  • Compositions useful as protein kinase inhibitors
    Patent number: 7456190
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: March 11, 2004
    Date of Patent: November 25, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Francois Maltais, Alex Aronov, Michael R. Hale, Young-Choon Moon
  • Inhibitors of aspartyl protease
    Patent number: 7442718
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: October 28, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael R Hale, Christopher T Baker, Timothy A Stammers, Ronald G Sherrill, Andrew Spaltenstein, Eric S Furfine, Francois Maltais, Clarence W Andrews, III, John F Miller, Vicente Samano
  • Sulfonamide inhibitors of aspartyl protease
    Patent number: 7419967
    Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods For inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.
    Type: Grant
    Filed: August 25, 2005
    Date of Patent: September 2, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael R Hale, Clarence W Andrews, III, Eric S Furfine, Ronald G Sherrill, Andrew Spaltenstein, Gregory T Lowen
  • Heteroaryl compounds useful as inhibitors or protein kinases
    Patent number: 7407962
    Abstract: The present invention provides compounds that are inhibitors of protein kinase, particularly inhibitors of ERK2, GSK3, PKA, CDK2 protein kinases, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment of various disorders.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: August 5, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alex Aronov, Michael R. Hale, Francois Maltais, Qing Tang
  • Isoxazole compositions useful as inhibitors of ERK
    Patent number: 7354919
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors, especially inhibitors of ERK, having the formula: where A, B, R1, R2, T and Ht are described in the specification. The compounds are useful for treating diseases in mammals that are alleviated by a protein, kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: July 24, 2003
    Date of Patent: April 8, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael R. Hale, James W. Janetka, Francois Maltais, Jingrong Cao
  • Protein kinase inhibitors and uses thereof
    Patent number: 7304071
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formulae I and V: or a pharmaceutically acceptable salt thereof, wherein Ring B, Z1, Z2, U, T, m, n, p, Q, Q?, R1, R2, Rx, R3, and R6 are as defined herein. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including stroke, inflammatory disorders, autoimmune diseases such as SLE lupus and psoriasis, proliferative disorders such as cancer, and conditions associated with organ transplantation.
    Type: Grant
    Filed: August 12, 2003
    Date of Patent: December 4, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: John Cochran, Jeremy Green, Michael R. Hale, Brian Ledford, Francois Maltais, Suganthini Nanthakumar
  • Triazole-derived kinase inhibitors and uses thereof
    Patent number: 6962936
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where Ht, R2, T, and m are as described in the specification. The compounds are useful for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: November 8, 2005
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael R. Hale, Francois Maltais
  • Evaporative cooler
    Patent number: D505193
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: May 17, 2005
    Inventor: Michael R. Hale